Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2120878 | 0.79 | — | — | |
| SCHEMBL1454256 | 0.77 | — | — | |
| SCHEMBL2119938 | 0.77 | USP2 (0.44) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL8960459 | 0.75 | USP2 (0.38) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL1062616 | 0.74 | — | — | |
| SCHEMBL10081318 | 0.72 | USP2 (0.65) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL1313662 | 0.72 | — | — | |
| SCHEMBL1760701 | 0.71 | MAPT (0.55) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL8382273 | 0.71 | MAPT (0.55) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL2520528 | 0.71 | MAPT (0.55) | USP2CYP3A4SMN1; SMN2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768693-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | Okinawa Institute of Science and Technology School Corporation (JP) | 2021-01-27 | — | — | EP | disclosed |
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| WO-2019182087-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OSTC, FUT6, FUT5 | USP2 3423/4885CYP3A4 1350/4885SMN1; SMN2 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.